<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003742</url>
  </required_header>
  <id_info>
    <org_study_id>98-100</org_study_id>
    <secondary_id>CDR0000066860</secondary_id>
    <secondary_id>NCI-G99-1495</secondary_id>
    <nct_id>NCT00003742</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>Phase I Trial of Paclitaxel, Cisplatin, and Irinotecan in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating&#xD;
      patients with locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of paclitaxel when combined with&#xD;
      cisplatin and irinotecan in patients with locally advanced or metastatic solid tumors. II.&#xD;
      Determine the dose limiting toxicity of paclitaxel when combined with cisplatin and&#xD;
      irinotecan in this patient population. III. Establish the recommended phase II dose for this&#xD;
      regimen in this patient population. IV. Assess the antitumor activity of this regimen in&#xD;
      selected solid tumor malignancies.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of paclitaxel. All patients receive paclitaxel IV&#xD;
      over 1 hour, then cisplatin IV over 30 minutes, followed by irinotecan IV over 30 minutes&#xD;
      weekly for 4 weeks on days 1, 8, 15, and 22. Treatment is repeated every six weeks for at&#xD;
      least 3 courses in the absence of disease progression or unacceptable toxicity. Cohorts of&#xD;
      3-6 patients receive escalating doses of paclitaxel. If 2 or more patients experience dose&#xD;
      limiting toxicity (DLT) at a particular dose level, escalation ceases and the maximum&#xD;
      tolerated dose (MTD) is defined as the previous dose level. Patients are followed until&#xD;
      death.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 12-27 patients will be accrued for this study within 6-9&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <completion_date type="Actual">August 2001</completion_date>
  <primary_completion_date type="Actual">August 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven locally advanced (unresectable or recurrent)&#xD;
        or metastatic solid tumor No bone metastases, abnormal radionuclide bone scan or pleural&#xD;
        effusions as the sole indicators of disease No CNS metastases or carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life&#xD;
        expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Neutrophil count at least&#xD;
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL&#xD;
        AST no greater than 3 times upper limit of normal (ULN) (no greater than 5 times ULN if&#xD;
        liver metastases present) No Gilbert's Disease Renal: Creatinine no greater than 1.5 mg/dL&#xD;
        Serum calcium less than 12.0 mg/dL No symptomatic hypercalcemia Cardiovascular: No unstable&#xD;
        angina No active angina No New York Heart Association class III or IV heart disease No&#xD;
        uncontrolled asymptomatic congestive cardiac failure At least 6 months since any myocardial&#xD;
        infarction Pulmonary: No interstitial pulmonary fibrosis Other: No history of seizure&#xD;
        disorder and receiving phenytoin, phenobarbital, or other antiepileptic medication No&#xD;
        active or uncontrolled infection No uncontrolled diabetes mellitus Not pregnant or nursing&#xD;
        Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: One prior&#xD;
        chemotherapy regimen allowed Endocrine therapy: Not specified Radiotherapy: At least 4&#xD;
        weeks since prior radiotherapy and recovered No prior mantle, hemibody, pelvic, or lumbar&#xD;
        spine irradiation Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Ilson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>March 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2004</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

